StreetInsider.com News Articles

PreveCeutical closes second tranche of private placement for $245,000

Fri, 12 Jun 2026 17:41:14 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced the completion of a second tranche of its non-brokered private placement, raising $245,000 through the issuance of 9.8 million units priced at $0.025 each.

The company previously closed an initial tranche on May 12, 2026, which raised $340,000 through 13.6 million units. Combined proceeds from both tranches totaled $585,000.

Each unit consists of one common share and one-half of a share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 per share for two years from the closing date. The company retains an acceleration right that can shorten the

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Fri, 12 Jun 2026 17:39:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 9,800,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $245,000. The Company closed an initial tranche (the "Initial Tranche") on May 12, 2026, consisting

PreveCeutical Closes Second Tranche of Non-Brokered Private Placement

Fri, 12 Jun 2026 17:39:00 -0400

BioGene Therapeutics appoints Ty Howton to board of directors

Mon, 08 Jun 2026 03:02:18 -0400

BioGene Therapeutics Inc. appointed Ty Howton to its board of directors, effective immediately, according to a statement from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0).

Howton brings nearly 30 years of biopharmaceutical industry experience, including 15 years in executive roles at public and private companies. He currently serves as Chief Operating Officer of Solid Biosciences, a clinical-stage gene therapy company, where he oversees daily operations and has helped advance multiple candidates into clinical trials.

His previous executive positions include Chief Operating Officer and General Counsel of AavantiBio, which merged with Solid Biosciences in 2022, and Executive Vice President, General Counsel

BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors

Mon, 08 Jun 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately. Mr. Howton has extensive board and governance experience, having previously served as Board Counsel and Corporate Secretary for Solid Biosciences, AavantiBio, Sarepta Therapeutics, and Vertex Pharmaceuticals, as well as Advisor to the Board on Health

BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors

Mon, 08 Jun 2026 03:00:00 -0400

PreveCeutical extends private placement deadline to June 12

Tue, 19 May 2026 19:37:14 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced it has extended the closing date of its non-brokered private placement to June 12, 2026, and plans to close a second tranche by the same date.

The offering aims to raise $1,000,000 through the sale of units. Each unit consists of one common share and one-half share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 each for two years from closing, subject to acceleration provisions if shares trade at $0.10 or higher for ten consecutive trading days on the Canadian Securities Exchange.

The company stated it intends to

PreveCeutical Announces Extension of Non-Brokered Private Placement

Tue, 19 May 2026 19:36:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has extended the closing of its private non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") to raise gross proceeds of $1,000,000 to June 12, 2026 and intends to close a second tranche of the Offering on or before June 12, 2026.

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of

PreveCeutical Announces Extension of Non-Brokered Private Placement

Tue, 19 May 2026 19:36:00 -0400

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of

PreveCeutical closes $340,000 initial tranche of private placement

Tue, 12 May 2026 17:03:16 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) completed the initial tranche of its previously announced $1,000,000 non-brokered private placement, raising $340,000 through the issuance of 13,600,000 units at $0.025 per unit.

Each unit consists of one common share and one-half of one share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 per share for two years from the closing date. The company retains an acceleration right to shorten the warrant expiry period to 30 days if shares trade at $0.10 or higher for 10 consecutive trading days on the Canadian Securities Exchange.

The company paid $23,600

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Tue, 12 May 2026 17:02:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (each, a "Unit") of the Company at a price of $0.025 per Unit for gross aggregate proceeds of $340,000.

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and

PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement

Tue, 12 May 2026 17:02:00 -0400

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and

PreveCeutical announces $1 million private placement offering

Wed, 22 Apr 2026 03:03:15 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced a non-brokered private placement offering of up to 40 million units at $0.025 per unit for gross proceeds of up to $1 million.

Each unit consists of one common share and one-half of a share purchase warrant. The warrants allow holders to purchase additional shares at $0.05 per share for two years from closing. The warrant expiry can be accelerated if the company's share price on the Canadian Securities Exchange reaches $0.10 or higher for 10 consecutive trading days.

The company stated it intends to use proceeds for short loan repayments, audit

PreveCeutical Announces Non-Brokered Private Placement

Wed, 22 Apr 2026 03:00:00 -0400

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 40,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.025 per Unit for gross proceeds of up to $1,000,000. Each Unit consists of one (1) common share of the Company (each, a "Share") and one-half (1/2) of one Share purchase warrant (each whole

PreveCeutical Announces Non-Brokered Private Placement

Wed, 22 Apr 2026 03:00:00 -0400

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

PreveCeutical Medical appoints Dr. Raj Pruthi to board of directors

Mon, 30 Mar 2026 03:02:15 -0400

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) announced the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its board of directors. The Vancouver-based health sciences company develops preventive and curative therapies using organic and nature-identical products.

Dr. Pruthi brings more than 20 years of experience in academic medicine, pharmaceutical leadership, and biotechnology. He currently serves as Chief Medical Officer of Relmada Therapeutics, Inc., a position he has held since June 2025, where he leads development of the NDV-011 bladder cancer program.

From 2022 to 2024, Dr. Pruthi held senior leadership roles in oncology at Johnson & Johnson Innovative

PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Mon, 30 Mar 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce the appointment of Dr. Raj S. Pruthi, MD, MHA, FACS, to its Board of Directors.

Dr. Pruthi is an accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation. In his new role, he will contribute to shaping the Company's clinical development strategy and advancing key initiatives,

PreveCeutical Medical Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Mon, 30 Mar 2026 03:00:00 -0400

BioGene Therapeutics appoints Raj Pruthi as director

Thu, 12 Mar 2026 03:02:11 -0400

BioGene Therapeutics Inc. has appointed Raj S. Pruthi, MD, MHA, FACS, as a director, according to an announcement from PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0), which holds a significant stake in BioGene.

Dr. Pruthi currently serves as Chief Medical Officer at Relmada Therapeutics, Inc., a position he has held since June 2025. At Relmada, he leads the development of the NDV-011 program for bladder cancer and oversaw fundraising efforts that raised over $100 million in net proceeds through a public offering and an additional $160 million through a private investment.

Prior to his role at Relmada, Dr. Pruthi served

BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Thu, 12 Mar 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"), a company that it is a significant shareholder of, has appointed Raj S. Pruthi, MD, MHA, FACS, as a Director of the Company. Dr. Pruthi, a renowned physician-scientist, executive leader, and board-level strategist with over two decades of experience in academic medicine, global pharmaceutical leadership, and biotechnology innovation, will lead BioGene's clinical strategy and advance its

BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as Director

Thu, 12 Mar 2026 03:00:00 -0400

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

Wed, 25 Feb 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - February 25, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce that the Canadian Patent Office has allowed Canadian Patent Application No. 3127020, titled "A Cyclic Peptide", which relates to the Company's pain therapy program. This allowance represents a significant milestone in the protection of PreveCeutical's proprietary technologies aimed at addressing unmet needs in pain management.

The Canadian patent application is directed novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse

PreveCeutical Announces Canadian Patent Office Allowance of Innovative Pain Therapy Technology

Wed, 25 Feb 2026 03:00:00 -0400

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Mon, 09 Feb 2026 03:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".

The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson's disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2^nd most common neurodegenerative disorder after dementia. Progressive

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Mon, 09 Feb 2026 03:00:00 -0400